• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Prioritizing between second-generation SARS-CoV-2 vaccines through low-dosage challenge studies

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2021 Feb 13;S1201-9712(21)00124-7.
doi: 10.1016/j.ijid.2021.02.038. Online ahead of print.
Prioritizing between second-generation SARS-CoV-2 vaccines through low-dosage challenge studies


Bastian Steuwer[SUP] 1 [/SUP], Euzebiusz Jamrozik[SUP] 2 [/SUP], Nir Eyal[SUP] 3 [/SUP]



Affiliations

Abstract

Design of human challenge studies balances scientific validity, efficiency, and study safety. This Perspective explores some advantages and disadvantages of "low-dosage" challenge studies, in the setting of testing second-generation vaccines against COVID-19. Compared to a conventional vaccine challenge, a low-dosage vaccine challenge would be likelier to start, and start earlier. A low-dosage challenge would also be less likely to rule out a vaccine candidate which would have been potentially effective in target usage. A key ethical advantage of a low-dosage challenge over conventional challenge is that both it and its dose escalation process are safer for each participant. Low-dosage studies usually require larger numbers of participants than conventional challenges, but this and other potential disadvantages are less serious than they may initially appear. Overall, low-dosage challenges should be considered for certain roles, such as prioritizing between second-generation vaccines against COVID-19.

Keywords: Coronavirus; Ethics; Human Challenge Studies; Research Design; Vaccines.
 
Back
Top Bottom